LY Full Year 2024 Earnings: RM0.01 loss per share (vs RM0.017 loss in FY 2023)
Net loss: RM5.07m (loss narrowed by 38% from FY 2023).
RM0.01 loss per share (improved from RM0.017 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
LY shares are down 4.5% from a week ago.
It's necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with LY (at least 2 which are concerning), and understanding these should be part of your investment process.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Krystal Biotech Second Quarter 2025 Earnings: Beats Expectations
Explore Krystal Biotech's Fair Values from the Community and select yours Krystal Biotech (NASDAQ:KRYS) Second Quarter 2025 Results Key Financial Results Revenue: US$96.0m (up 37% from 2Q 2024). Net income: US$38.3m (up 146% from 2Q 2024). Profit margin: 40% (up from 22% in 2Q 2024). The increase in margin was driven by higher revenue. EPS: US$1.33 (up from US$0.54 in 2Q 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period Krystal Biotech Revenues and Earnings Beat Expectations Revenue exceeded analyst estimates by 4.4%. Earnings per share (EPS) also surpassed analyst estimates by 14%. Looking ahead, revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 12% from a week ago. Risk Analysis It is worth noting though that we have found 1 warning sign for Krystal Biotech that you need to take into consideration. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
a minute ago
- Yahoo
MOGU Full Year 2025 Earnings: CN¥7.14 loss per share (vs CN¥6.85 loss in FY 2024)
Explore MOGU's Fair Values from the Community and select yours MOGU (NYSE:MOGU) Full Year 2025 Results Key Financial Results Revenue: CN¥141.2m (down 12% from FY 2024). Net loss: CN¥62.6m (loss widened by 5.5% from FY 2024). CN¥7.14 loss per share (further deteriorated from CN¥6.85 loss in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period MOGU shares are down 2.9% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 1 warning sign for MOGU you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
a minute ago
- Yahoo
Sohu.com Second Quarter 2025 Earnings: US$0.69 loss per share (vs US$1.16 loss in 2Q 2024)
Explore Fair Values from the Community and select yours (NASDAQ:SOHU) Second Quarter 2025 Results Key Financial Results Revenue: US$126.3m (down 27% from 2Q 2024). Net loss: US$20.0m (loss narrowed by 47% from 2Q 2024). US$0.69 loss per share (improved from US$1.16 loss in 2Q 2024). This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. All figures shown in the chart above are for the trailing 12 month (TTM) period Earnings Insights Looking ahead, revenue is forecast to stay flat during the next 3 years compared to a 10% growth forecast for the Entertainment industry in the US. Performance of the American Entertainment industry. The company's shares are down 3.4% from a week ago. Risk Analysis You should always think about risks. Case in point, we've spotted 1 warning sign for you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
